The American Journal of Medicine
Volume 121, Issue 2 , Pages 89-90 , February 2008

Surveillance of Hepatocellular Carcinoma: We Must Do Better

References 

  1. Bruix J, Sherman M Practice Guidelines Committee American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  2. Bruix J, Sherman M, Llovet JM, et al. Conclusions of the Barcelona-2000 EASL conference European Association for the Study of the Liver Clinical management of hepatocellular carcinoma. J Hepatol. 2001;35:421–430
  3. Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008;121:119–126
  4. Chalasani N, Said A, Ness R, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol. 1999;94:2224–2229
  5. Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol. 2007;5:508–512
  6. Davila JA, Weston A, Smalley W, El-Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2007;41:777–782
  7. El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158–166
  8. Tanaka H, Nouso K, Kobashi H, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int. 2006;26:543–551
  9. Kim DY, Han KH, Sang HA, et al. Semiannual surveillance for hepatocellular carcinoma improved patient survival compared to annual surveillance (Korean experience). Hepatology. 2004;6(Suppl 1):368
  10. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003;163:218–224
  11. Snyder N, Gajula L, Xiao SY, et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2006;40:535–542
  12. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6
  13. Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004;40:1352–1360
  14. Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol. 2007;21:491–500

PII: S0002-9343(07)01144-8

doi: 10.1016/j.amjmed.2007.11.004

The American Journal of Medicine
Volume 121, Issue 2 , Pages 89-90 , February 2008

Article Tools